The Runx genes are important in development and cancer, where they can act either as oncogenes or tumour suppressors. We compared the effects of ectopic Runx expression in established fibroblasts, where all three genes produce an indistinguishable phenotype entailing epithelioid morphology and increased cell survival under stress conditions. Gene array analysis revealed a strongly overlapping transcriptional signature, with no examples of opposing regulation of the same target gene. A common set of 50 highly regulated genes was identified after further filtering on regulation by inducible RUNX1-ER. This set revealed a strong bias toward genes with annotated roles in cancer and development, and a preponderance of targets encoding extracellular or surface proteins, reflecting the marked effects of Runx on cell adhesion. Furthermore, in silico prediction of resistance to glucocorticoid growth inhibition was confirmed in fibroblasts and lymphoid cells expressing ectopic Runx. The effects of fibroblast expression of common RUNX1 fusion oncoproteins (RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11) were also tested. Although two direct Runx activation target genes were repressed (Ncam1 and Rgc32), the fusion proteins appeared to disrupt the regulation of downregulated targets (Cebpd, Id2 and Rgs2) rather than impose constitutive repression. These results elucidate the oncogenic potential of the Runx family and reveal novel targets for therapeutic inhibition.
Introduction
The mammalian genes play unique and non-redundant roles in normal development, as indicated by disruptions of Runx1, 2 or 3, which give rise to severe deficits in definitive haemopoiesis, bone formation and neurogenesis, respectively (Wang et al., 1996; Otto et al., 1997; Ducy et al., 1999; Levanon et al., 2002; Inoue et al., 2002) . The gene family has also been widely implicated in cancer where they can be involved both as tumour suppressors and oncogenes according to the context (Speck and Gilliland, 2002; Ito, 2004; Blyth et al., 2005) . The oncogenic potential of the Runx genes has been demonstrated by their occurrence as targets for retroviral activation in lymphomas of CD2-MYC mice (Stewart et al., 1997 Wotton et al., 2002) and confirmed in CD2-Runx2 transgenic mice, which are prone to lymphoma development (Vaillant et al., 1999; Blyth et al., 2001) . The human RUNX1 can also play a dominant oncogenic role in myeloid leukaemias and childhood B-cell leukaemias through the formation of fusion proteins such as RUNX1-ETO or TEL-RUNX1 by common chromosomal translocation events (Speck and Gilliland, 2002) . The tumour-suppressive potential of this family has been demonstrated most clearly for RUNX1, where haploinsufficiency leads to familial platelet disorder, a rare syndrome that entails predisposition to myeloid leukaemia (Song et al., 1999) , and somatic loss of function mutations are observed affecting one or both alleles of RUNX1 in acute myeloid leukaemias (Osato et al., 1999) . Evidence for a tumour suppressor role for RUNX3 comes mainly from the observation that this gene is frequently downregulated and hypermethylated in various epithelial cancers (Ito, 2004) .
The context-specific factors that determine which facet of Runx behaviour is observed are beginning to be understood. In primary murine fibroblasts Runx1 induces senescence-like growth arrest, but this response is lost in cells lacking Arf or p53 function (Linggi et al., 2002; Wotton et al., 2004) , which instead acquire tumorigenic properties (Wotton et al., 2004) . Ectopic expression of Runx2 in the thymus induces growth arrest in immature T cells, but this effect is neutralized by co-expression of Myc, and the potent combination of Runx2 and Myc drives rapid tumour expansion (Blyth et al., 2001; Vaillant et al., 2002) . Although antiapoptotic functions have been implicated (Blyth et al., 2006 ), the precise mechanisms by which the Runx genes manifest their oncogenic effects remain largely unknown. Another important question is the extent of functional redundancy between the Runx family members and whether the tissue-specific manifestations of their tumour-suppressive potential are due merely to their distinctive patterns of transcription or reflect their unique functional attributes.
The three Runx genes encode the a-chains of the core binding factor complex that bind directly to their consensus target sequences, with high-affinity interaction conferred by a common non-DNA-binding cofactor, Cbfb (Huang et al., 1999) . Binding of the core binding factor complex to target promoters can result in recruitment of either activating or repressing complexes (Lutterbach et al., 2000) , and the classic example of this functional duality is provided by the opposing effects of Drosophila Runt on the slp1 gene in adjacent embryonal segments (Swantek and Gergen, 2004) . The factors regulating this transcriptional switch are not fully understood, but are likely to involve the availability of cofactors as well as post-translational modifications of the Runx proteins themselves (Bae and Lee, 2006) . A large number of Runx target genes have already been identified and these include essential components of lineage-specific differentiation programmes which operate in haemopoietic, osteoblastic and neurogenic precursor cells as well as regulators of basic cellular processes and cell-cycle control (Otto et al., 2003) . It is clear that the Runx transcriptome varies according to cell type, and that understanding Runx regulation in cancer requires the development of cell models that display a relevant phenotype. In this study, we have explored the effects of ectopic expression in immortalized fibroblasts. Our results show that Runx1, 2 and 3 induce a similar phenotype and direct a strongly overlapping transcriptional programme with a common set of target genes that provide novel insights into the pleomorphic effects of Runx expression on cell behaviour and growth regulation.
Results
The Runx genes induce epithelioid transformation and enhanced survival in established murine fibroblasts We have shown previously that Runx1 can induce morphological transformation and promote tumorigenicity in p53-null primary murine fibroblasts (mouse embryonic fibroblast, MEF) whereas wild-type cells undergo premature senescence in the presence of ectopic Runx expression (Wotton et al., 2004; Kilbey et al., 2007) . For the present study we chose to use 3T3 fibroblasts that display a more uniform phenotype compared to MEFs but share permissiveness for Runx expression by virtue of their lack of Ink4a (p16/p19) expression. Into these cells we introduced the full-length P1 isoforms of Runx1, 2 and 3. The transduced cells displayed an epithelioid transformation phenomenon similar to that observed in MEFs (Figure 1a ; Wotton et al., 2004) with a phenotypic shift resembling mesenchymal to epithelial transition (MET; Chaffer et al., 2007) . Other key features of this phenotype included a profound alteration in the distribution of N-cadherin in favour of the plasmamembrane ( Figure 1b ) and markedly increased expression of integrin b5 (Figure 1c) .
Although the proliferation rate of Runx-expressing cells was not found to be increased, a potentially important survival advantage was noted, particularly under conditions of stress such as medium exhaustion. This phenomenon is illustrated in Figure 1d where the death rates of control and Runx-expressing cell cultures held at confluence, with periodic medium change, are compared. Although results for Runx1 are illustrated, essentially identical observations were made for the other two genes. Ectopic Runx expression was stable and readily detected in these cells by western blot analysis (Figure 1e ).
The Runx genes regulate a strongly overlapping transcriptional programme To analyse the Runx phenotype at the level of global transcriptional changes, we harvested RNA from newly confluent cultures which displayed the most marked phenotypic alteration and carried out a gene expression microarray analysis, comparing cells expressing vector only with those transfected with each of the Runx genes. The primary array data have been deposited in the Gene Ontology Omnibus (accession number pending). Large number of genes were found to be changed, with a more or less equal number up-or down-regulated ( Figure 2a ). However, a striking overlap was observed between the three genes. This is illustrated clearly in the bar diagrams in Figure 2b , where the 150 genes falling within the 1% false discovery rate (FDR) cutoff are grouped according to their regulation by one or more of the Runx genes. Extending the window to 10% FDR increased representation to encompass 81% of the genes showing regulation by more than one family member. Moreover, analysis of genes beyond this cutoff shows that, with few exceptions, these are similarly albeit more weakly regulated by other family members (not shown). Strikingly, we found no examples of genes that were significantly regulated by one family member (5% FDR) and regulated in the opposite direction by another family member. These results suggest that Runx transcriptional function is highly conserved, although clearly some divergence in regulatory potency has developed over evolutionary distances.
To gain further insight into modes of Runx regulation, a functionally inducible Runx protein (RUNX1-ER) was introduced into the same fibroblast cells, and transcriptional profiles were compared after 24 h of 4-hydroxytamoxifen (4-OHT) induction. Complete conversion of this fusion protein to its transcriptionally active form was confirmed by its rapid and stable posttranslational modification in the presence of inducer (Figure 2c) . Most of the target gene set displayed significant regulation under these conditions and we used this criterion as a further filter to define a subset of 50, Runx-modulated genes that are candidates for direct regulation (Figure 2c ).
Runx genes regulate many targets with established roles in cancer and development Extensive validation was carried out to confirm the robustness of the array data. Figure 3a compares the results of the fold-change measurements for a subset of genes, on replicate chips with analysis by quantitative (qt) real-time-PCR (RT-PCR). As can be seen, there was a very strong correspondence across a large and representative subset of the target genes.
The 50-gene Runx target set was analysed further with the aid of bioinformatics programmes (Figure 3b ). The most highly over-represented Gene Ontology terms were identified (http://david.abcc.ncifcrf.gov/), showing a remarkable preponderance of genes encoding cellsurface or extracellular ligands (36%). Regulated genes encoding cell-surface proteins included Itgb5, indicating that transcriptional control is involved in its upregulation by Runx noted earlier ( Figure 1c ). As smaller gene sets required fewer recorded hits to reach statistical significance, the occurrence of three enzymes involved in sphingolipid metabolism was also noteworthy (Sgpp1, Ugcg and St3gal5). Sorting according to over-represented biological functions (www.ingenuity.com) was also highly informative, revealing many with annotated roles in cancer (32%), and molecular and cellular processes including cellular development (26%), cellular growth and proliferation (40%). The top 50 genes are listed in Table 1 along with the fold-change estimates from the array analysis and annotations according to the bioinformatic groupings defined in Figure 3b .
Few previously identified Runx targets were present in the gene set, emphasizing the cell type-specific nature of the Runx transcriptome. For most targets listed in Table 1 , the most intense regulation was noted for Runx3. This was probably due in most cases to the high Runx3 expression that was achieved in this experiment, as indicated by further biological replicates and realtime PCR measurements (not shown), but it is likely that there are some real quantitative differences as some genes showed markedly more potent regulation by Runx3 compared to constitutive Runx1 and 2 expressing cells. A notable example is Timp4.
Validation of direct Runx targets
A number of known and novel Runx targets were selected for closer examination and determination of the regulatory mechanisms involved. A 24 h induction period allows time for many indirect changes to transcript levels and gives only a preliminary indication of those genes under direct regulation. We therefore . (e) Runx1, 2 and 3 expression in 3T3 cells detected by western blotting using a pan-runx antibody. As this antibody reacts most efficiently with Runx3 and least efficiently with Runx2, a separate panel is shown where Runx2 is detected with a specific Runx2 antibody. Cells over-expressing Runx1 (6i) and Runx2 (47i) are included as controls (Stewart et al., 1997; Wotton et al., 2002) .
Runx targets in cell adhesion and survival S Wotton et al examined the kinetics of change in transcript levels on induction of RUNX1-ER with 4-OHT for a set of six genes ( Figure 4a ). This analysis showed that three of the selected genes were rapidly and strongly regulated (Cebpd, Rgc32 and Rgs2) whereas two others showed a complex response where an initial dip in transcript levels preceded induction (Cyp1b1 and Itgb5). The sixth gene, Nr3c1, showed an early but relatively modest level of regulation. As a further test for direct regulation, we examined the requirement for protein synthesis by inducing RUNX1-ER in the presence of cycloheximide. Although interpretation of these experiments was complicated by the non-specific effects of cycloheximide on the stability of some transcripts, it was clear that induction of Rgc32 and repression of Rgs2 were insensitive to cycloheximide inhibition, whereas Nr3c1 downregulation was completely abolished (not shown).
Further support for direct regulation of the most strongly regulated genes (Cebpd, Rgc32 and Rgs2) was obtained by scanning the promoter regions for consensus Runx target sites and confirming occupancy of these sites in vivo by chromatin immunoprecipitation (ChIP; Figure 4b ). It appears, therefore, that induction kinetics may be a useful predictor of the mode of Runx regulation.
Runx expression mediates resistance to glucocorticoid-mediated growth arrest and apoptosis Despite the presence of many genes relevant to cancer, the highly regulated gene set revealed few candidate mediators of apoptosis control. A prominent exception was Nr3c1, the gene encoding glucocorticoid receptor, which was consistently downregulated in the presence of each of the three Runx genes (Table 1 ) and quite rapidly modulated by RUNX1-ER, albeit by an apparently indirect mechanism. In silico prediction of glucocorticoid resistance was tested directly by exposing Runx expressing fibroblasts to dexamethasone (Figure 5a ). In empty vector-transduced cells, dexamethasone was found to be strongly growth inhibitory to control cells and induced death above background levels. Both effects were much less marked in cells expressing Runx1.
Runx expression is markedly anti-apoptotic in T-cell lymphoma in vivo (Blyth et al., 2006) so we extended the functional analysis to T cells in vitro by expressing Runx1 in readily transduced T-cell lymphoma cell lines established from p53-null mice (Blyth et al., 1995) . A similar level (twofold) of downregulation of Nr3c1 in the presence of ectopic Runx was found by qt-RT-PCR as had been observed in the fibroblasts. Although the lymphocytes over-expressing Runx1 showed no obvious survival advantage in the absence of stress, resistance to dexamethasone-induced apoptosis was seen in highdensity cultures. Results for one such line (pm97) are shown in Figure 5b .
RUNX1 oncoproteins disrupt Runx target gene regulation but do not behave as constitutive repressors
In human leukaemia, RUNX1 is a frequent target for chromosomal translocations that result in N or Cterminal fusions of truncated RUNX1 proteins to heterologous partners. As the major RUNX1 fusion partners (ETO and TEL) harbour transcriptional repression domains that recruit corepressors such as histone deacetylases to the target promoters, it has been postulated that these fusion events convert RUNX1 from a conditional transcriptional activator/ repressor to a constitutive repressor of its target genes (Fenrick et al., 1999; Amann et al., 2001) . A similar hypothesis has been advanced to explain the oncogenic potential of the CBFB/MYH11 fusion in which a truncated version of the common RUNX cofactor CBFB is conjoined with a smooth muscle myosin isoform (Durst et al., 2003) . To test this model further, we expressed RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11 in 3T3 cells (Figure 6a ). These cells did not adopt the characteristic Runx morphology and displayed no significant difference in growth or survival characteristics (not shown).
Quantitative RT-PCR analysis of representative genes from the Runx target set is shown in Figure 6 . Two of the target genes (Ncam1 and Rgc32) behaved as predicted according to the constitutive repression model, with reduced expression in the presence of all the three fusion proteins. However, none of the Runxrepressed target genes showed a similar response to the fusion oncoproteins, and showed instead a tendency toward de-repression compared to control cells. In particular, Cepbd was markedly increased in the presence of the CBFB-MYH11 fusion. These results do not support the constitutive repressor model for the fusion oncoproteins.
Discussion
In this study we have shown that ectopic expression of the three Runx genes in the same cell background induces an indistinguishable phenotype and a strongly overlapping change in global transcription patterns. These observations confirm and greatly extend previous studies based on a small number of target genes which suggested a high degree of functional redundancy in the Runx family, despite their acquisition of unique Table 1 ). The most common Gene Ontology terms and associated P-values (http://david.abccncifcrf.gov/) are listed at the top of the figure. Top biological functions and associated P-values were based on Ingenuity Pathways Analysis (www.ingenuity.com). The range of P-values refers to subcategories within each heading. The top two categories are listed for diseases and disorders, molecular and cellular functions, and physiological system development and function. The group numbers correspond to functional annotations listed in Table 1 .
Runx targets in cell adhesion and survival S Wotton et al developmental roles during vertebrate evolution (Javed et al., 2000) . Quantitative differences may be significant, however, and could account for the failure of chimeric genes with C-terminal elements of Runx2 and Runx3 to completely rescue haemopoietic development in Runx1-deficient mice (Fukushima-Nakase et al., 2005) . The phenotype conferred by Runx expression in 3T3 fibroblasts is also of interest and potentially revealing List of 50 common target genes selected on the basis of similar regulation by Runx1, 2 and 3 and inducible regulation by RUNX1-ER. The basis of filtration of the gene sets is shown in Figure 2 . Upregulated and downregulated genes are listed separately in alphabetical order. The fold-change levels estimated from duplicate chips are indicated for each Runx gene. Functional annotation (*) is based on the occurrence of each target gene in the sets defined in Figure 3b .
Runx targets in cell adhesion and survival S Wotton et al with regard to the complex relationship of the Runx genes to cancer development. We have described the phenotype as epithelioid transformation, based on our previous observations on p53À/À MEFs which adopt a similar phenotype and display increased tumorigenicity under the influence of ectopic Runx expression (Wotton et al., 2004) . This process resembles MET, the mirror image of the process commonly associated with invasive potential in cancer. Although this might appear to represent a tumour-suppressive or anti-metastatic feature of Runx, it should be noted that MET may be important in establishing tumours at new niches after metastatic spread (Chaffer et al., 2007) . Moreover, our previous studies in MEFs showed that Runx1 slows but does not prevent epithelial to mesenchymal transition in the presence of transforming growth factor-b (Wotton et al., 2004) . The survival advantage we have described here may be more a decisive factor than cell morphology in the increased tumorigenicity of Runxexpressing cells. The transcriptional signature of ectopic Runx expression reflects both the epithelioid phenotype and the ambiguous roles of the Runx genes in cancer. Thus, the upregulated set included genes over-expressed in cancer or associated with increased survival (Ccl2, Cyp1b1, Itgb5, Ncam1, Rgc32 and Ugcg) whereas the downregulated set included numerous genes with tumoursuppressive or anti-proliferative potential (Cebpd, Egln3, Errfi1/Mig6, Gas2, Nr3c1, Rgs2, Sgpp1 and Tob2). However, other genes displayed the contrary relationship with upregulation of some ligands that have been reported to inhibit tumorigenic potential (Ccl7 and Timp4) and downregulation of putative oncogenic or pro-survival factors (Alcam, Kitl, Msln and Six1). Other genes from the set have context-specific roles analogous to the Runx family (Angptl4, Id2 and Id3).
A surprising feature of the present study was the paucity of Runx-regulated genes with an annotated role in control of apoptosis, suggesting that the Runx genes exploit a novel set of pathways to increase cell survival. As the glucocorticoid receptor gene, Nr3c1, is downregulated by all three Runx genes, albeit indirectly, we tested the sensitivity of Runx expressing cells to dexamethasone. We found significantly increased resistance in both fibroblast cells and in lymphoid cells. These results are of considerable interest in light of the profound anti-apoptotic effects of Runx2 expression in the lymphoid compartment in vivo, particularly in the context of Myc oncogene over-expression (Blyth et al., 2006) . It seems unlikely that glucocorticoid receptor downregulation alone is sufficient to explain the marked resistance we observed, and it is notable that the common Runx target set also includes enzymes involved in sphingolipid metabolism (Sgpp1, Ugcg and St3gal5) that have been shown to be involved in apoptosis regulation (Bleicher and Cabot, 2002; Le Stunff et al., 2002) and in cross-talk with glucocorticoid-induced inhibitory signals (Bianchini et al., 2006) . It will be of interest to explore the wider role of Runx regulation in ceramide-sphingosine metabolism and tumour chemoresistance. In this regard it is also interesting to note that the Runx genes emerged as preferred targets for retroviral activation in a murine model of imatinib resistance (Miething et al., 2007) and that the latter phenomenon has been linked in vitro to altered ceramide metabolism (Baran et al., 2007) .
Finally, we tested the effects of ectopic expression of the three most important core binding factor fusion proteins which arise from chromosomal rearrangements in human leukaemia (RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11). A model has been advanced, whereby the fusion proteins act as constitutive repressors of Runx gene targets, whereas the normal Runx complexes are able to activate or repress the same targets in a contextspecific manner (Fenrick et al., 1999; Amann et al., 2001; Durst et al., 2003) . These models are based largely on the use of exogenous reporter constructs based on model promoters or natural activation targets for Runx such as T-cell antigen receptorb. Although we found that some activation targets of Runx behaved in the predicted manner (Ncam1 and Rgc32), displaying strong activation by all three wild-type genes and repression by all the three fusion oncoproteins, the Runx-repressed genes showed an unexpected pattern where the fusion proteins generally disrupted or reversed repression. This could not simply be ascribed to indirect regulation, as a number of unequivocal direct targets showed similar behaviour (Cebpd and Rgs2). We suggest that a more complex model is required to account for the behaviour of the fusion proteins that may be able, for example, to disrupt or destabilize Runx-repressive complexes at target gene promoters. The operation of alternative Runx-repressive mechanisms such as inhibition of transcriptional elongation should also be considered (Jiang et al., 2005) and it is notable that the Runx binding site we mapped in Rgs2 lies within the transcription unit. Whatever the mechanism involved, these results reinforce the view that the unique oncogenic properties of the fusion proteins entail more than merely loss of Runx function.
Materials and methods

Cells and constructs
The fibroblast cell line was derived from the NIH 3T3 cell line and maintained as previously described (Mann et al., 1983) . Lymphocyte cell lines were previously established from p53-null mice and grown as described (Blyth et al., 1995) . Retroviral vectors were based on the pBabe plasmid (Morgenstern and Land, 1990) , carrying the puromycin selectable marker. The Runx1 construct contains a 1.6 kb cDNA fragment encoding the Runx1P1 isoform; the Runx2 is a 2.3 kb fragment encoding the Runx2P1 isoform; the Runx3 is a 1.3 kb fragment encoding the Runx3P1 isoform. All were subcloned into the polylinker region of pBabe-PURO. The RUNX1-ER construct (pBabe-AML-ER) has been previously described (Lou et al., 2000) and encodes the RUNX1P1 isoform conjoined to a modified oestrogen receptor (hereafter referred to as pBabe-RUNX1-ER) inducible in the presence of 4-OHT (Sigma-Aldrich, Gillingham, Kent, UK). 4-OHT dissolved in ethanol (0.1 mM) was added at a final concentration of 200 nM. Equivalent volumes of ethanol were added to control cultures. AML-1/ETO (RUNX1-ETO) and CBFB-MYH11 (Inv16) constructs were obtained as clones in the pBabe-PURO plasmid whereas the TEL-RUNX1 construct Runx targets in cell adhesion and survival S Wotton et al was kindly subcloned into pBabe-PURO by K Wolyniec. The vector control was the empty pBabe-PURO plasmid.
Transfections, transductions and culture conditions Transfections were carried out using Superfect Transfection Reagent (Qiagen, Crawley, UK) according to the manufacturer's protocol for transient transfection of adherent cells. Fibroblasts were plated at 8 Â 10 5 in 10 cm dishes and incubated overnight before transfection. Transfected fibroblasts were then incubated overnight in normal medium after which selection was applied using puromycin (Sigma) at 2 mg/ml for 4 days. Control fibroblasts died under these selection conditions. Puromycin selection was continued throughout. Medium changes were carried out every 3-4 days and post-confluent cultures were maintained in 25 cm 2 flasks without passage. pBabe-Runx1P1-PURO and the control plasmid were introduced into lymphocytes by retroviral transduction using Phoenix packaging cells as described previously (Wotton et al., 2004) . Viral supernatants were filtered through 0.45 mm filters, supplemented with 4 mg/ml polybrene (Sigma) and used to infect lymphocyte cultures (1 Â 10 6 cells). After an initial infection overnight, a second harvest of viral supernatant was added for a further 8 h. Cells were allowed to recover overnight in fresh medium and selection was applied using 2 mg/ml puromycin for 6 days.
Live/dead cell counts were carried out using a haemocytometer and Trypan blue as a vital indicator. Graphs were generated with Sigma-Plot and significance values determined by Student's t-test. Error bars relate to standard deviations.
Western blotting and antibodies
Preparation of whole cell protein extracts was performed as described previously (Wotton et al., 2004) . Samples equivalent to 30 mg total protein (Bio-Rad protein assay) were resolved on 8, 10 or 17% SDS-polyacrylamide gels and transferred to enhanced chemiluminescence (ECL; Amersham, Little Chalfont, UK) nitrocellulose membranes. The antibodies used were ERa-sc542; b-actin-(I-19) sc1616 (Santa Cruz Biotechnology, Santa Cruz, USA); Runx3 (pan-Runx) rabbit polyclonal antibody (in house); Runx2/CBFa1 clone 8G5 (MWG no. D130-3).
Immunofluorescent labelling and confocal microscopy Immunofluorescence was performed as described previously . Runx-expressing and control fibroblasts were plated at 2 Â 10 4 per well and grown to 80% confluence on 13.3 mg/ml poly-L-lysine-coated glass chamber slides (two wells per slide). Primary antibodies used were 1:100 a-Ncadherin-610921 (BD Transduction Laboratories, Frampton, Dorset, UK) and 1:500 a-integrin b5-ab15459 (ABCAM, Cambridge, UK). An appropriate fluorescein (fluorescein isothiocyanate)-conjugated antibody (Jackson Laboratories, via Stratech Scientific, Newmarket, Suffolk, UK), diluted 1:100 in block buffer was used as secondary antibody.
Microarray
Runx-expressing and control fibroblasts were grown to confluence in duplicate wells (7 days). Cells expressing the RUNX1-ER construct were treated for a further 24 h with 4-OHT. Cells were harvested from duplicate wells into buffer RLT and RNA prepared using the RNeasy Mini kit (Qiagen) according to the manufacturers' protocol. cDNA preparation and the microarray assay and primary analysis were performed in the Sir Henry Wellcome Functional Genomics Facility at the University of Glasgow using standard Affymetrix protocols and GlaMA analysis approach (http:www.brc.dcs.gla.ac.uk/systems/glama/) implemented locally into the FunAlyse automated pipeline. Briefly, duplicate samples were hybridized to Affymetrix GeneChip Mouse Genome 430.2.0 arrays representing over 34 000 genes. Raw data were then normalized by the Robust Multichip Average method (Irizarry et al., 2003) and differentially expressed genes were identified by the Rank Products Algorithm (Breitling et al., 2004) , which is particularly powerful for analysis of small numbers of biological replicates (Breitling and Herzyk, 2005; Jeffery et al., 2006) .
Quantitative real-time PCR cDNA was prepared from RNA isolated as above or by RNABee (AMS Biotechnology, Oxford, UK) as previously described (Kilbey et al., 2007) . Aliquots (5 ml) of cDNA were amplified in triplicate using primers for murine endogenous control Hprt as previously described (Kilbey et al., 2007) or primers for murine Cyp1b1, Itgb5, Rgc32, Timp4, Cebpd, ErrFi1, Nr3c1, Sgpp1 (Qiagen QuantiTect Primer Assays), Ncam1 (619F 5 0 -acaaaggccgagatgtcattct-3 0 and 697R 5 0 -atgcccctgatctgcaggta-3 0 ), Ugcg (779F 5 0 -tttgctcagtacattgctgaa gatta-3 0 and 861R 5 0 -acttgagtagacattgaaaacctccaa-3 0 ), Id2 (370F 5 0 -ccaccctgaacacggacatc-3 0 and 456R 5 0 -agagtactttgctat cattcgacataagc-3 0 ), Rgs2 (273F 5 0 -ggcagaagcatttgatgaactg-3 0 and 375R 5 0 -caaccagaattcaatgttttcttcac-3 0 ). Relative quantification was carried out and calibrated to vector control samples.
Chromatin immunoprecipitation assay ChIP was performed as described for the Active Motif ChIP-IT kit with modifications. Approximately 5 Â 10 7 cells were treated with 1% (v/v) formaldehyde at room temperature for 10 min. Crosslinking was terminated by adding 0.125 M glycine for 5 min. Cells were washed in ice cold phosphate buffered saline and collected by centrifugation at 4 1C for 10 min at 2500 r.p.m. The pellet was resuspended in lysis buffer (ChIP-IT kit) and incubated on ice for 30 min. Following Dounce homogenization (15 strokes) the nuclei were collected by centrifugation at 4 1C for 10 min at 5000 r.p.m., resuspended in 2 ml shearing buffer (ChIP-IT kit) and sonicated on ice to a DNA size of 300-600 bp. Precleared chromatin (50 ml) was immunoprecipitated with 2 mg of antibody and immuncomplexes collected by magnetic binding to Dyna beads protein G 100.03D (Invitrogen, Paisley, UK). Beads were washed eight times in 800 ml wash buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.6, 0.5 M LiCl, 1 mM EDTA pH 8.0, 1% NP40, 7% sodium deoxycholate) and three times in 1X TE. Immunocomplexes were eluted twice in 50 mM NaHCO 3 and 1% (v/v) SDS at 65 1C for 15 min, adjusted to 200 mM NaCl and incubated overnight at 65 1C to reverse crosslinking. Following treatment with RNaseA (100 mg/ml) and Proteinase K (200 mg/ml) each sample was purified through a DNA purification column (ChIP-IT kit). One-tenth of the immunoprecipitated DNA and one-hundredth of input DNA were analysed by PCR using oligonucleotides: Bglap2(f)- The antibodies used were: a-RUNX2 and a-GST (Santa Cruz Biotechnology sc-10758, sc-459).
Dexamethasone treatment Runx1-expressing fibroblasts or lymphocytes and control cells were plated at 1 Â 10 6 per well per 2 ml and dexamethasone (10 mM; D2915; Sigma) was added after 24 h. Drug sensitivity was tested by Trypan blue exclusion assay and live/dead counts.
Note added in proof
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE11732 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11732).
